The patent protects technology which improves HbA1c stability, precision and accuracy and has resulted in a longer product shelf-life with improved performance. The invention may also have utility for the NycoCard product for the same marker.
Ian Gilham, Axis-Shield CEO, said: “We are developing a strong franchise for measuring HbA1c in diabetes through Afinion and NycoCard at the point-of-care and on the Abbott AxSYM analyser in the hospital laboratory. We are pleased to have been granted this patent as part of our program to protect our innovative technology in the expanding near-patient testing marketplace.”